서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 8 of 8

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2003-11	Up-regulation of cytoskeletal-associated protein 2 in primary human gastric adenocarcinomas Bae, CD; Sung, YS; Jeon, SM; Suh, Y; Yang, HK; Kim, YI; Park, KH; Choi, J; Ahn, G; Park, J Journal of Cancer Research and Clinical Oncology, Vol.129 No.11, pp.621-630	DOI
2004-12	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma Sun, Jong-Mu; Han, Wonshik; Im, Seock-Ah; Kim, Tae-You; Park, In Ae; Noh, Dong-Young; Heo, Dae Seog; Bang, Yung-Jue; Choe, Kuk Jin; Kim, Noe Kyeong Cancer, Vol.101 No.11, pp.2516-2522	DOI
2005-11	Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas Im, Seock Ah; Lee, Kyung Eun; Nam, Eunmi; Kim, Do Yeun; Lee, Joo-Ho; Han, Ho-Seong; Seoh, Ju-Young; Park, Hae-Young; Cho, Min-Sun; Han, Woon Sup; Lee, Soon Nam Tumori, Vol.91 No.6, pp.513-521	DOI
2011-05	Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab Chang, Hye Jung; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Jeon, Yoon Kyung; Park, In Ae; Han, Wonshick; Noh, Dong-Young; Bang, Yung-Jue; Kim, Tae-You Japanese Journal of Clinical Oncology, Vol.41 No.5, pp.593-599	DOI
2012-07	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer Han, Sae-Won; Cha, Yongjun; Paquet, Agnes; Huang, Weidong; Weidler, Jodi; Lie, Yolanda; Sherwood, Thomas; Bates, Michael; Haddad, Mojgan; Park, In Hae; Oh, Do-Youn; Lee, Keun Seok; Im, Seock-Ah; Bang, Yung-Jue; Ro, Jungsil; Kim, Tae-You PLoS ONE, Vol.7 No.7, p. e0039943	DOI
2014-05	Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas Seo, A. N.; Yang, J. M.; Kim, H.; Jheon, S.; Kim, K.; Lee, C. T.; Jin, Y.; Yun, S.; Chung, J-H; Paik, J. H. British Journal of Cancer, Vol.110 No.11, pp.2688-2699	DOI
2015-05	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) Blumenschein, G. R., Jr.; Smit, E. F.; Planchard, D.; Kim, D. -W.; Cadranel, J.; De Pas, T.; Dunphy, F.; Udud, K.; Ahn, M. -J.; Hanna, N. H.; Kim, J. -H.; Mazieres, J.; Kim, S. -W.; Baas, P.; Rappold, E.; Redhu, S.; Puski, A.; Wu, F. S.; Jaenne, P. A. Annals of Oncology, Vol.26 No.5, pp.894-901	DOI
2017-05	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer Park, Sehhoon; Kim, Ji-Yeon; Lee, Se-Hoon; Suh, Beomseok; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.32 No.3, pp.514-522	view file DOI

1